非甾体抗炎药使用与炎症性肠病加重的关联:真实关联还是残余偏倚?
该队列研究纳入2004-2015年炎症性肠病患者,分别有15,705例(44.8%)和19,326例(55.2%)使用和未使用非甾体抗炎药。传统Cox模型显示非甾体抗炎药与炎症性肠病加重相关(HR 1.24),但暴露前同样存在类似关联(HR 1.30),自控病例系列分析提示反向因果导致潜在混杂,传统关联可能继发于残余偏倚。
要点
- 传统Cox模型显示非甾体抗炎药暴露与炎症性肠病加重相关(HR 1.24)。
- 非甾体抗炎药暴露前的加重风险同样升高(HR 1.30),提示残余混杂。
- 自控病例系列分析提示0-2周暴露后发病率较高,可能为反向因果。
核心结论
- 传统方法观察到非甾体抗炎药与炎症性肠病加重的关联,但进一步分析提示该关联可能继发于残余偏倚。
研究设计与样本
- 研究为队列研究,纳入2004-2015年炎症性肠病患者,采用倾向性匹配、校正Cox比例风险模型、前事件率比和自控病例系列分析三种方法。
主要发现
- 共识别15,705例(44.8%)非甾体抗炎药暴露患者和19,326例(55.2%)非暴露患者。
- Cox比例风险模型提示非甾体抗炎药与炎症性肠病加重相关(风险比1.24;95%置信区间1.16-1.33)。
- 非甾体抗炎药暴露组在暴露前的炎症性肠病加重可能性相似(风险比1.30;95%置信区间1.21-1.39)。
- 对3,968例同时有非甾体抗炎药暴露和炎症性肠病加重的患者进行自控病例系列分析,暴露前1年、暴露后2-6周和暴露后6周至6个月的加重率相似,但暴露后0-2周发病率较高。
临床怎么用
- 作者认为这些发现可能让考虑将非甾体抗炎药作为非阿片类疼痛管理选择的患者和临床医生感到安心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies suggest that nonsteroidal anti-inflammatory drugs (NSAID) may contribute to inflammatory bowel disease (IBD) exacerbations. We examined whether variation in the likelihood of IBD exacerbations is attributable to NSAID. METHODS: In a cohort of patients with IBD (2004-2015), we used 3 analytic methods to examine the likelihood of an exacerbation after an NSAID exposure. First, we matched patients by propensity for NSAID use and examined the association between NSAID exposure and IBD exacerbation using an adjusted Cox proportional hazards model. To assess for residual confounding, we estimated a previous event rate ratio and used a self-controlled case series analysis to further explore the relationship between NSAID and IBD exacerbations. RESULTS: We identified 15,705 (44.8%) and 19,326 (55.2%) IBD patients with and without an NSAID exposure, respectively. Findings from the Cox proportional hazards model suggested an association between NSAID and IBD exacerbation (hazard ratio 1.24; 95% confidence interval 1.16-1.33). However, the likelihood of an IBD exacerbation in the NSAID-exposed arm preceding NSAID exposure was similar (hazard ratio 1.30; 95% confidence interval 1.21-1.39). A self-controlled case series analysis of 3,968 patients who had both an NSAID exposure and IBD exacerbation demonstrated similar exacerbation rates in the 1 year preceding exposure, 2-6 weeks postexposure, and 6 weeks to 6 months postexposure, but a higher incidence in 0-2 weeks postexposure, suggesting potential confounding by reverse causality. DISCUSSION: While we see an association between NSAID and IBD exacerbations using traditional methods, further analysis suggests this may be secondary to residual bias. These findings may reassure patients and clinicians considering NSAID as a nonopioid pain management option.
引用
- Cohen-Mekelburg S, Van T, Wallace B, et al. The Association Between Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease Exacerbations: A True Association or Residual Bias? Am J Gastroenterol. 2022. PMID: 35970816. doi:10.14309/ajg.0000000000001932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。